Abbott: Afinion™ 2 analyzer

For the use only of registered medical practitioners or a hospital or a laboratory.

Point-of-care testing (POCT) is a rapidly developing field in medical technology, which focuses on bringing accurate testing for various conditions directly to the site of patient care. Abbott’s Afinion™ 2 analyzer is an advanced, easy to use and patient friendly offerings for testing requirements related to diabetes screening and monitoring.

The Afinion™ 2 analyzer is the result of years of continuous product innovation and refinement and delivers actionable point-of-care test results in just minutes. With its compact size and panel of tests, the Afinion™ 2 system is ideal for point-of-care testing in physician offices, clinics, community health centers, retirement homes, emergency rooms, and hospital outpatient clinics. From just a fingerstick sized sample, highly accurate results for HbA1c, ACR, lipid panel, and CRP are made available during the consultation.

Consultations with patients who do not have their lab results are challenging and inefficient. Point-of-care HbA1c testing can improve operational efficiency and lead to increased patient motivation and satisfaction^1-4. Point-of-care testing leads to reduced workload in the practice including fewer follow-up calls, fewer follow-up letters, and fewer patient revisits³. More informed decision-making improves patient-clinician relationships and patient motivation and attitude.

The Afinion™ HbA1c is a simple fingerstick test that provides a patient’s HbA1c value in three minutes, during the consultation. It is highly accurate and requires very small sample volume. It is US FDA cleared, CLIA waived, NGSP, and IFCC certified and has no interference from common hemoglobin variants. Afinion™ HbA1c has 24 months shelf life and 3 months of room temperature storage. It has ready-to-use controls in two levels. The Afinion™ 2 analyzer has a simple 3 step procedure and can reliably transfer test results to an information system. To view what experts have to say on the relevance of in-clinic point of care testing go to alere.wistia.com/medias/9cbraypvvh/.

1. Shepard MD. Clin Biochem Rev. 2006;27(3):161-70.
2. Miller CD, Barnes CS, Phillips LS, et al. Diabetes Care. 2003;26(4):1158-63.
3. Crocker JB, Lee-Lewandrowski E, Lewandroski N, et al. Am J Clin Pathol. 2014;142:640-6.
4. Laurence CO, Gialamas A, Bubner T. Br J Gen Pract. 2010;60(572):e98-e104.

© 2021 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. This material has been developed as a service to the medical profession. The information is being made available purely as measure of awareness. No part of this material may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of Abbott. This material does not purport to explain any specific method of treatment in a comprehensive manner and is meant only for the registered medical practitioners, hospitals or laboratories. While every effort has been made to ensure that the information in this material is accurate and up-to-date, Abbott and Alere Medical Pvt Ltd shall not be liable in any manner whatsoever for any action on the basis of this work and does not hold itself for any consequences, legal or otherwise, arising out of such information. The users shall solely be responsible for their actions and are requested to refer other specific sources for more details/clarifications. 10006301 03/21.